In the ERSPC Goteborg subset, biennial screening for 20 years led to a 56% prostate cancer mortality reduction13, while in the Rotterdam subset, PSA screening resulted in a 51% reduction with no difference in treatment arms14. This evidence concerns the gene KLK3 and prostate carcinoma.